 MONT-SAINT-GUIBERT, Belgium, May 19, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that it has received a transparency notification dated 14 May 2021 indicating that Victory Capital Management Inc., now has crossed the statutory threshold of 5, holding 713,214 shares i.e. 4.11 of Celyad Oncologys shares and voting rights as of 13 May 2021. 